The debate over how to handle conflicts of interest among experts appointed to US government advisory panels heated up today (July 24), as the Food and Drug Administration (FDA) announced it will look more closely at how it manages the issue on its science panels.For instance, the agency plans to revise the guidelines used to determine when an expert with a conflict of interest deserves a waiver, typically issued when the conflict is deemed to be insignificant, or the scientist's expertise too great to lose. In addition, the FDA plans to look at ways to improve explaining to the public why some scientists received waivers. "There's more we can do to simplify how we communicate the criteria we use to give waivers," FDA deputy commissioner for medical scientific affairs Scott Gottlieb told The Scientist.The FDA's plan to review its policy on waivers follows the introduction of a bill in...
Center for Science in the Public InterestNational Academy of SciencesThe ScientistCurt FurbergSteven Nissenamccook@the-scientist.comClarification (posted July 25): When originally posted, the article implied that the FDA kept the COX-2 inhibitor Bextra on the market. FDA asked Pfizer to withdraw Bextra in April, 2005.The Scientisthttp://www.the-scientist.com/article/display/20970/http://www.fda.gov/oc/guidance/advisorycommittee.htmlhttp://thomas.loc.gov/cgi-bin/bdquery/z?d109:h.r.02090:http://www.cspinet.org/http://www.nationalacademies.org/http://www.nhlbi.nih.gov/health/allhat/furberg.htmhttp://www.clevelandclinic.org/heartcenter/pub/staff/searchdetail.asp?staffid=1185
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?